Description

Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that regulates glucose metabolism by increasing the activity of incretin hormones. It enhances insulin secretion and decreases glucagon levels in a glucose-dependent manner.

This research-grade compound is used in pharmacological and metabolic studies involving glycemic control, incretin biology, and type 2 diabetes modeling. Each tablet contains 5mg of Linagliptin, with a total of 28 tablets per bottle.

Manufactured by Hangzhou Minsheng Pharmaceutical Co., Ltd. under NMPA approval H20243434. Product code: 86904494003236.

?? For research use only. Not intended for clinical or diagnostic use.

Product Specifications

Mechanism & Research Applications

Linagliptin works by inhibiting the enzyme DPP-4 (dipeptidyl peptidase-4), which prolongs the activity of incretin hormones such as GLP-1 and GIP. These hormones help regulate insulin and glucagon levels in response to meals, improving glycemic control.

This compound is widely used in the following research applications:

• Type 2 diabetes mellitus modeling

• Glucose-stimulated insulin secretion studies

• DPP-4 enzyme inhibition assays

• Incretin hormone dynamics research

• Comparative studies with other antidiabetic agents

Safety & Handling

• Use Restriction: For laboratory research only

• Protective Equipment: Gloves, lab coat, and eye protection

• Storage: Keep sealed and stored below 25°C

• Disposal: Follow institutional chemical disposal protocols

Research Use Disclaimer

This product is intended solely for laboratory research. It is not approved for use in humans or animals for therapeutic, diagnostic, or veterinary purposes. Misuse may result in safety or regulatory consequences. Follow proper biosafety and institutional protocols at all times.